WeLeader Biomedical Co., Ltd. (TPEX:7713)

Market Cap	3.37B
Revenue (ttm)	1.06B
Net Income (ttm)	191.02M
Shares Out	45.48M
EPS (ttm)	4.33
PE Ratio	17.10
Forward PE	n/a
Dividend	3.37 (4.55%)
Ex-Dividend Date	Jun 3, 2025

Volume	17,720
Average Volume	16,892
Open	74.00
Previous Close	74.00
Day's Range	74.00 - 74.50
52-Week Range	54.20 - 86.00
Beta	n/a
RSI	49.62
Earnings Date	Nov 10, 2025

About WeLeader Biomedical

WeLeader Biomedical Co., Ltd. operates as an agent and distributor of in vitro diagnostic products. It offers a range of medical testing systems, such as serum biochemistry integration platform, clinical care, and medical information integration system. The company also provides blood gas electrolyte analyzers, urine analyzers, integrated fully automatic biochemical analyzers, fully automatic electronic luminescence immunoassay products, fully automatic modular biochemical immune assay products, TTA automated pre-processing products, POCT centr...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1992
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 7713

Financial Performance

In 2024, WeLeader Biomedical's revenue was 991.13 million, an increase of 5.36% compared to the previous year's 940.70 million. Earnings were 170.21 million, an increase of 11.77%.